Anti-estrogen adjuvant treatments are the first line of therapy for management of breast cancer in patients (>67% of total patients) whose tumors are estrogen receptor positive (ER+); such treatments reduce the degree of 15-year mortality by ~33% [1]. The gene discussed is ESR1; the disease is breast cancer.